Edwards Lifesciences (NYSE: EW) CFO trades 13K shares under 10b5-1 plan

Rhea-AI Filing Summary

Edwards Lifesciences CVP and Chief Financial Officer Scott B. Ullem exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and sold 13,000 shares in open-market transactions. The sales occurred in two tranches at weighted average prices of $80.4963 and $79.7866 per share under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025. After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, resulting in a net reduction of 13,000 shares in his position.

Insights

Equity compensation and insider trading analyst

CFO executes routine option exercise-and-sell under a 10b5-1 plan.

Scott B. Ullem, CFO of Edwards Lifesciences, exercised employee stock options for 13,000 shares at an exercise price of $59.2567 and sold the same 13,000 shares in the market at weighted average prices near $80 per share. This is a classic exercise-and-sell pattern that converts options into cash.

The filing shows these trades were effected under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025, which suggests the timing was scheduled in advance rather than opportunistic. Following the transactions, Ullem still directly owns 39,699 shares and indirectly holds 266,318 shares through a trust, indicating he retains a substantial equity stake.

There are no remaining derivatives listed in the derivative summary, implying this specific option grant has been fully exercised. The net change is a sale of 13,000 shares relative to his combined direct and indirect holdings, a modest proportion that looks like routine portfolio management rather than a thesis-changing move.

Insider Trade Summary 10b5-1

Net Seller: 13,000 shares ($1,040,544)

Net Sell 5 txns

Insider Ullem Scott B.

Role CVP, Chief Financial Officer

Sold 13,000 shs ($1.04M)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	13,000	$0.00	--
Exercise	Common Stock	13,000	$59.2567	$770K
Sale	Common Stock	4,676	$80.4963	$376K
Sale	Common Stock	8,324	$79.7866	$664K
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 13,000 shares (Direct); Common Stock — 52,699 shares (Direct); Common Stock — 266,318 shares (Indirect, By Trust)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Options exercised: 13,000 shares Exercise price: $59.2567 per share Shares sold tranche 1: 4,676 shares at $80.4963 +4 more

7 metrics

Options exercised 13,000 shares Employee stock option exercise at $59.2567 per share on April 9, 2026

Exercise price $59.2567 per share Strike price for 13,000-share employee stock option

Shares sold tranche 1 4,676 shares at $80.4963 Open-market sale of common stock on April 9, 2026

Shares sold tranche 2 8,324 shares at $79.7866 Second open-market sale of common stock on April 9, 2026

Net shares sold 13,000 shares Transaction summary netBuySellShares for reported trades

Direct holdings after 39,699 shares Total common stock directly owned after transactions

Indirect holdings after 266,318 shares Common stock held indirectly by trust after transactions

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Acquire), weighted average sale price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Acquire) financial

"security_title: "Employee Stock Option (Right to Acquire)""

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"ownership_type: "indirect", nature_of_ownership: "By Trust""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ullem Scott B.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/09/2026		M(1)		13,000	A	$59.2567	52,699	D
Common Stock	04/09/2026		S(1)		4,676	D	$80.4963(2)	48,023	D
Common Stock	04/09/2026		S(1)		8,324	D	$79.7866(3)	39,699	D
Common Stock								266,318	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	04/09/2026		M			13,000	05/08/2020	05/07/2026	Common Stock	13,000	$0.0000	13,000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Edwards Lifesciences (EW) CFO Scott B. Ullem report?

Scott B. Ullem reported exercising employee stock options for 13,000 Edwards Lifesciences shares at $59.2567, then selling 13,000 shares in open-market trades. The sales occurred at weighted average prices of $80.4963 and $79.7866 per share on April 9, 2026.

Were the recent Edwards Lifesciences (EW) CFO share sales pre-planned?

Yes. The filing states all reported transactions were executed under a Rule 10b5-1 trading plan adopted by Scott B. Ullem on July 29, 2025. Such plans pre-schedule trades, reducing the significance of the specific timing for interpreting insider sentiment.

How many Edwards Lifesciences (EW) shares does the CFO hold after these trades?

After the reported transactions, CFO Scott B. Ullem holds 39,699 Edwards Lifesciences shares directly. He also has indirect ownership of 266,318 shares through a trust, according to the holding entry in the Form 4 filing.

What prices did the Edwards Lifesciences (EW) CFO receive for the sold shares?

The CFO’s 13,000 Edwards Lifesciences shares were sold in two weighted-average price tranches. One tranche of 4,676 shares averaged $80.4963, while another 8,324-share tranche averaged $79.7866, with individual trades executed within stated price ranges.

Did the Edwards Lifesciences (EW) CFO retain any options after this Form 4 exercise?

The Form 4 shows a 13,000-share employee stock option exercised at $59.2567 with no remaining derivative positions listed in the derivative summary. This suggests that particular option grant was fully exercised in connection with the reported transactions.

What was the net effect of the Edwards Lifesciences (EW) CFO’s transactions on his holdings?

The transaction summary reports net sell activity of 13,000 shares. Scott B. Ullem exercised options for 13,000 shares and sold 13,000 shares, ending with 39,699 shares held directly plus 266,318 shares held indirectly through a trust.